


**Product Name** : TRi-1  
**Cat. No.** : PC-63164  
**CAS No.** : 246020-68-8  
**Molecular Formula** : C<sub>12</sub>H<sub>9</sub>ClN<sub>2</sub>O<sub>5</sub>S  
**Molecular Weight** : 328.723  
**Target** : STAT  
**Solubility** : 10 mM in DMSO



### Biological Activity

TRi-1 (TXNRD1 inhibitor 1) is a potent, specific and irreversible inhibitor of cytosolic **thioredoxin reductase 1** (TXNRD1, TrxR1) with anticancer potential, 5- to 10-fold higher specificity for TXNRD1 over TXNRD2.

TRi-1 block **STAT3**-dependent transcriptional activity with IC<sub>50</sub> of 2.9 uM in IL6-STAT3 luciferase reporter assays, 8-fold selectivity over IFN-γ STAT1.

TRi-1 inhibits cellular TXNRD activity with equal or greater potency compared to that of Auranofin with no effect on cellular GSH concentrations, efficiently activates c-Jun N-terminal kinase (JNK) and p38 phosphorylation.

TRi-1 shows cytotoxicity profile against the NCI-60 cell panel with mean IC<sub>50</sub> of 6.41 uM.

TRi-1 impairs growth and viability of human tumor xenografts and syngeneic mouse tumors while having little mitochondrial toxicity and being better tolerated than auranofin.

### References

Stafford WC, et al. *Sci Transl Med*. 2018 Feb 14;10(428). pii: eaaf7444.

2. S Busker, et al. *Sci Adv*. 2020 Mar 20;6(12):eaax7945.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com